Challenges and Opportunities for Nucleic Acid Therapeutics.
Nucleic Acid Ther
; 32(1): 8-13, 2022 02.
Article
en En
| MEDLINE
| ID: mdl-34931905
After decades overcoming difficult problems, antisense oligonucleotide (ASO), duplex RNA (siRNA), and messenger RNA (mRNA) nucleic acid therapeutic strategies are finally demonstrating clinical benefits. This success presents new challenges. What goals remain for basic research? Will there be an explosion of clinical applications that benefit many patients with different diseases, or will success be restricted to diseases that are ideal for the application of current technologies? The aim of this perspective is to describe a selection of the major goals for the next decade.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Oligonucleótidos
/
Oligonucleótidos Antisentido
Límite:
Humans
Idioma:
En
Revista:
Nucleic Acid Ther
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos